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Summary
Background In a previous randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in 
patients with acute respiratory distress syndrome (ARDS) reduced extravascular lung water and plateau airway 
pressure. We assessed the eﬀ ects of this intervention on mortality in patients with ARDS.
Methods We did a multicentre, placebo-controlled, parallel-group, randomised trial at 46 UK intensive-care units 
between December, 2006, and March, 2010. Intubated and mechanically ventilated patients (aged ≥16 years) within 
72 h of ARDS onset were randomly assigned to receive either salbutamol (15 μg/kg ideal bodyweight per
 
h) or placebo 
for up to 7 days. Randomisation was done by a central telephone or web-based randomisation service with minmisation 
by centre, pressure of arterial oxygen to fractional inspired oxygen concentration (PaO2/FIO2) ratio, and age. All 
participants, caregivers, and investigators were masked to group allocation. The primary outcome was death within 
28 days of randomisation. Analysis was by intention-to-treat. This trial is registered, ISRCTN38366450 and EudraCT 
number 2006-002647-86.
Findings We randomly assigned 162 patients to the salbutamol group and 164 to the placebo group. One patient in 
each group withdrew consent. Recruitment was stopped after the second interim analysis because of safety concerns. 
Salbutamol increased 28-day mortality (55 [34%] of 161 patients died in the salbutamol group vs 38 (23%) of 163 in the 
placebo group; risk ratio [RR] 1∙47, 95% CI 1∙03–2∙08).
Interpretation Treatment with intravenous salbutamol early in the course of ARDS was poorly tolerated. Treatment is 
unlikely to be beneﬁ cial, and could worsen outcomes. Routine use of β-2 agonist treatment in ventilated patients with 
this disorder cannot be recommended.
Funding UK Medical Research Council, UK Department of Health, UK Intensive Care Foundation.
Introduction
Acute respiratory distress syndrome (ARDS) occurs in 
about 14% of mechanically ventilated patients, and 
causes a mortality of 40–60%1–3 and a substantial 
reduction in survivors’ quality of life.4–6 β-2 agonists 
could be a potential pharma cological intervention 
because they act on the many pulmonary cellular 
pathways thought to be associated with the patho-
physiology of ARDS. These drugs reduce neutrophil 
sequestration, activation, and production of inﬂ ammatory 
cytokines,7,8 and activate β-2 receptors on alveolar type-1 
and type-2 cells, which increases intracellular cyclic 
adenosine monophosphate, leading to increased sodium 
transport and acceleration of alveolar ﬂ uid reabsorption.9–11 
In patients with ARDS given salbutamol, we reported in-
vivo evidence of reduced permeability of alveolar 
capillaries, and in-vitro evidence of enhanced wound 
repair in epithelial monolayers.12 These data suggest that 
β-2 agonists could maintain alveolar-capillary integrity, 
thereby reducing alveolar ﬂ ooding.
Findings from the β-agonist lung injury trial 
(BALTI)13—a single-centre, randomised controlled trial in 
40 patients with ARDS—showed that an infusion of 
salbutamol for 7 days caused signiﬁ cant reductions in 
extravascular lung water and plateau airway pressure. 
However, this trial was not designed to assess the 
potential eﬀ ects on mortality. We therefore assessed 
whether treatment with salbutamol in the early course of 
ARDS would improve clinical outcomes.
Methods
Study design and participants
We undertook a multicentre, pragmatic, double-blind, 
placebo-controlled, parallel-group, randomised trial at 
46 UK intensive-care units between December, 2006, 
and March, 2010. Eligible participants were intubated 
and mechanically ventilated adults aged 16 years and 
older within 72 h of ARDS onset. Patients were identiﬁ ed 
and recruited by local investigators at each site. We 
deﬁ ned ARDS in accordance with the American 
European Consensus criteria:14 a pressure of arterial 
oxygen to fractional inspired oxygen concentration 
(PaO2/FIO2) ratio of 200 mm Hg or less, bilateral 
pulmonary inﬁ ltrates consistent with oedema, and the 
absence of clinically evident left atrial hypertension. 
Exclusion criteria were pregnancy; current treatment 
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with intravenous β-2 agonist or need for continuous, 
regular, aerolised β-2 agonists; current treatment with 
β-adrenergic antagonists; imminent withdrawal of 
medical treatment; chronic liver disease, deﬁ ned as 
Child-Pugh grade C; and enrolment in another clinical 
trial of an investigational medicinal product within the 
previous 28 days.
Sedated patients did not have capacity to give consent; 
therefore, consistent with requirements of the EU clinical 
trial directive,15 we obtained written informed consent 
from a personal or professional legal representative 
before randomisation. All surviving patients were 
informed about the trial at the earliest opportunity after 
regaining competence and consent to continue in the 
trial was sought. The study protocol16 was approved for all 
centres by the Oxfordshire Research Ethics Committee 
A. Site speciﬁ c approval was obtained at each site. The 
trial was monitored for safety by an independent Data 
Monitoring and Ethics Committee.
Randomisation and masking
Study drug packs were prepared by Bilcare Global 
Clinical Supplies (Europe; Powys, UK). The active and 
placebo drug components of the infusions were 
packaged identically into numbered treatment packs, 
each containing 5 mL of either salbutamol sulphate BP 
(1 mg/mL
 
in a sterile isotonic solution, GlaxoSmithKline, 
Middlesex, UK) or placebo (0·9% sterile sodium 
chloride). We used a computer-generated random-
isation sequence with a block size of eight. Patients 
were randomly assigned in a 1:1 ratio by a centralised 
24 h telephone or web-based randomisation service 
(Uni versity of Aberdeen, UK). Randomisation was 
minimised by centre, PaO2/FIO2 ratio (≤50, 51–99, or 
≥100 mm Hg), and age (<64, 65–84, ≥85 years). 
Participants, care providers, and investigators were 
masked to group assignment.
Procedures
We obtained acute physiology and chronic health 
evaluation II (APACHE II) scores from Intensive Care 
National Audit and Research Centre (ICNARC) for sites 
(n=36) that participate in the ICNARC’s Case Mix 
Programme or, for non-participating sites (ten), we 
obtained data necessary for calculation of the scores. We 
used the APACHE II score to calculate the mortality risk, 
which we used for subgroup analysis.
The most likely cause of ARDS was identiﬁ ed by the 
treating clinician and categorised as direct lung injury 
(smoke or toxin inhalation, aspiration of gastric content, 
near drowning, thoracic trauma, pneumonia, or other) or 
indirect lung injury (sepsis, cardiopulmonary bypass, 
pancreatitis, non-thoracic trauma, other). The protocol 
recommended use of a lung protective ventilation strategy 
on the basis of ideal bodyweight,17 ﬂ uid restriction,18 
and appropriate high positive end-expiratory pressure.19 
Compliance with recommendations for protective venti-
lation were assessed at baseline only (tidal volumes per 
kg ideal bodyweight). All other treatments were delivered 
in accordance with local clinical practice.
Before the start of recruitment, the intensive-care unit 
nurse was trained to monitor side-eﬀ ects of the treatment 
and to inform the research team as necessary. Infusion 
syringes were prepared immediately before use by the 
nurse and contained two ampoules of the blinded solu-
tions (salbutamol or placebo) diluted with 40 mL of saline 
in a 50 mL syringe. Salbutamol and placebo were 
administered through a dedicated intravenous line at a 
rate of 0∙075 mL/kg ideal bodyweight per h
 
(equivalent to 
15 μg salbutamol per kg ideal bodyweight per
 
h). The 
patient was measured from heel to vertex with a soft tape 
measure, and the ideal bodyweight and infusion rate 
obtained from the conversion table.17 If any patient 
developed a tachycardia (heat rate >140 beats per min), 
new arrhythmia, or lactic acidosis, we adjusted the 
infusion rate according to a prespeciﬁ ed dose-adjustment 
schedule.15 Infusion of the study drug was stopped at 
7 days, or earlier if clinically indicated.
Study outcomes
The primary outcome was 28-day mortality, deﬁ ned as 
death up to the end of calendar day 28 after random isation. 
Secondary outcomes were mortality in the intensive-care 
unit or hospital before ﬁ rst
 
discharge; ventilator-free and 
organ failure-free days from randomisation to day 28; 
length of stay in intensive-care unit and hospital; 
and tachycardia, new arrhythmia, or other side-eﬀ ects 
suﬃ  cient to stop treatment with trial drug. We deﬁ ned 
ventilator-free days as the number of calendar days after 
patients started unassisted breathing until day 28 after 
randomisation for patients who survived at least 48 con-
secutive hours after start of unassisted breathing.20 The 
number of ventilator-free days was zero for patients who 
died without start of unassisted breathing or before 
48 consecutive hours of unassisted breathing.20 We deﬁ ned 
326 patients underwent
 randomisation
162 assigned to 
 receive salbutamol
164 assigned to 
 receive placebo
160 received 
 salbutamol
2 not given drug
164 received placebo
1 withdrew 
 consent
1 withdrew 
 consent
161 included in 
 analysis
163 included in 
 analysis
Figure 1: Trial proﬁ le
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organ failure-free days as the number of days in the ﬁ rst 
28 days after randomisation that the patient received no 
cardiovascular, renal, liver, or neurological support as 
deﬁ ned by the Critical Care Minimum Dataset.21
We did not plan to collect data for cause of death in the 
original trial protocol; however, after early termination of 
the trial because of the increased 28-day mortality in the 
salbutamol group, the data for the main cause of death 
were ascertained for all participants dying within 28 days 
of randomisation. We requested causes of death as 
recorded on the death certiﬁ cate for the disorder directly 
leading to death. Patients who remained alive and in 
critical care after randomisation were monitored daily 
until discharged to a ward, or until day 28.
Statistical analysis
We based the sample-size calculation on our BALTI trial13 
and on 2005 data from the Intensive Care National 
Audit and Research Centre. The target sample size of 
1334 gave 90% power at p<0∙05 to detect a risk ratio (RR) 
of 0·8 for 28-day mortality between the salbutamol and 
placebo groups with a 3% loss of patients for the primary 
outcome, with the assumption that the 28-day mortality 
in the placebo group was 44%. We planned interim ana-
lyses every 12 months, or more frequently if requested by 
the Data Monitoring and Ethics Committee. The 
committee used the Haybittle-Peto22 stopping guideline: 
a diﬀ erence of three standard errors would be needed 
before considering recommending trial cess ation for 
beneﬁ t at an interim analysis.
All analyses were based on intention-to-treat analyses. 
We compared the primary outcome and other dichot omous 
outcomes using RRs and 95% CIs. We compared 
continuous outcomes with mean diﬀ erences and their 
95% CIs. We analysed 28-day mortality with survival 
analysis, and by comparison of the two groups with hazard 
ratios and 95% CIs and the Kaplan–Meier curve. All 
reported p values are two-sided and were not adjusted for 
multiple comparisons. We used prespeciﬁ ed sub group 
analyses to investigate the eﬀ ects of age, severity of 
hypoxaemia at study entry, cause (direct vs indirect causes 
of ARDS), and the APACHE II mortality risk, on the eﬀ ect 
of salbutamol. All subgroup analyses used interaction tests; 
we either calculated the ratio of RRs between the subgroups, 
or used interaction terms in logistic regression models. We 
did a post-hoc analysis for the main causes of death as 
recorded on the death certiﬁ cates of participants who died 
within 28 days of randomisation. This trial is registered, 
ISRCTN38366450 and EudraCT number 2006-002647-86.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. FGS, SG, GDP, and SEL had full 
access to all the data in the study, and the corresponding 
author had ﬁ nal responsibility for the decision to submit 
for publication.
Salbutamol (n=162) Placebo (n=164)
Age (years) 55·8 (17·2) 54·2 (17·5)
Male sex 102 (63%) 110 (67%)
Height (cm) 168·8 (10·8) 169·0 (12·2)
APACHE II score 19·5 (6·2) 18·9 (6·7)
APACHE II predicted mortality 0·43 (0·20) 0·42 (0·21)
Tidal volume (mL/kg ideal bodyweight) 8·0 (1·7) 8·3 (1·9)
PaO2 /FIO2 ratio (mm Hg) 103·5 (36·75) 103·5 (36·75)
100–200 82 (51%) 81 (49%)
51–99 74 (46%) 78 (48%)
≤50 6 (4%) 4 (2%)
Missing data 0 1
Cause of ARDS
Direct lung injury 103 (64%) 105 (64%)
Smoke or toxin inhalation 1 2
Gastric content aspiration 6 9
Near drowning 1 0
Thoracic trauma 5 9
Pneumonia 86 79
Drug related 2 1
Other 2 5
Missing data 1 0
Indirect lung injury 58 (36%) 59 (36%)
Sepsis 39 47
Cardiopulmonary bypass 1 1
Pancreatitis 6 4
Non-thoracic trauma 2 6
Transfusion related 6 1
Other 4 0
Time from ICU admission to randomisation (days) 2·7 (2·9) 2·5 (2·6)
Missing data 1 0
Data are mean (SD) or number (%), unless otherwise stated. PaO2 /FIO2=pressure of arterial oxygen to fractional 
inspired oxygen. APACHE II=acute physiology and chronic health evaluation II. ARDS=acute respiratory distress 
syndrome. ICU=intensive-care unit.
Table 1: Baseline characteristics
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Figure 2: Kaplan-Meier curves for duration of infusions
Duration of salbutamol and placebo infusions from 28 days after randomisation. 
HR=hazard ratio.
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Results
46 study sites participated in recruitment; a further 25 sites 
obtained approval to start the trial, but were unable to do 
so before recruitment was stopped. Recruitment was 
stopped after the second interim analysis, when the Data 
Monitoring and Ethics Committee reviewed the results 
for 273 patients in March, 2010. The RR for the primary 
outcome at this time was 1∙55 (95% CI 1∙07–2∙24). 
Therefore, the committee recommended suspension of 
recruitment to BALTI-2 because of a signiﬁ cant (p=0∙02) 
adverse eﬀ ect of salbutamol on 28-day mortality, and the 
99∙8% CI excluded a beneﬁ t for salbutamol of the size 
anticipated in the protocol. Infusion was discontinued in 
all patients (one receiving salbutamol, two receiving 
placebo) receiving study drug at that time. The trial 
steering committee endorsed this recommendation and 
closed recruitment on March 23, 2010.
Figure 1 shows the trial proﬁ le. 326 patients were 
randomly assigned to receive either salbutamol or 
placebo. Two patients withdrew consent; no outcome 
data were available for these patients. The study drug was 
not given to two patients in the salbutamol group: one 
patient needed a β blocker between randomisation and 
starting the drug, the other patient’s next of kin refused 
to have a separate intravenous line inserted for infusion 
after initially giving consent.
Both groups had similar baseline characteristics (table 1). 
The median time from randomisation to start of the study 
infusion was similar in both groups (salbutamol 1∙3 h, 
IQR 0∙6–2∙5; placebo 1∙1 h, 0∙6–2∙2). Patients in the 
salbutamol group were more likely to have their infusion 
stopped early than were those in the placebo group, either 
because of death (14/161 vs eight of 163), or the development 
of signiﬁ cant side-eﬀ ects (47/161 vs 13/163). The duration 
of infusion was on average 24∙5 h (95% CI 12·3–36·7) 
shorter in the salbutamol group than in the placebo group 
(mean 114∙1 h [SD 62∙7] vs 138∙6 h [47∙9]; ﬁ gure 2). The 
risks of patients developing a tachycardia, new arrhythmia, 
or lactic acidosis severe enough to warrant stopping of the 
study drug were substantially higher in the salbutamol 
group than in the placebo group (table 2).
More patients died 28 days after randomisation in the 
salbutamol group than in the placebo group (RR 1∙47, 
95% CI 1∙03–2∙08; p=0∙03; table 2). Survival analysis of 
the primary outcome (ﬁ gure 3) showed a hazard ratio of 
1·56 (95% CI 1·03–2·36). Salbutamol resulted in a 10∙9% 
(95% CI 1∙0–20∙4) absolute increase in 28-day mortality 
(table 2). One additional death occurred for every 9∙2 
(95% CI 4∙9–100∙9) patients with ARDS given salbutamol. 
The number of deaths before discharge from either 
intensive-care unit or hospital did not diﬀ er signiﬁ cantly 
between groups (p=0·10 and p=0·26, respectively; 
table 2). We noted an 8∙4% (95% CI –1∙7 to 18∙3) absolute 
increase in intensive-care unit mortality and a 6∙0% 
(–4∙4 to 16∙2) increase in hospital mortality in the 
salbutamol group (table 2).
Ventilator-free and organ failure-free days in the ﬁ rst 
28 days after randomisation were both reduced in the 
salbutamol group (table 2). We detected no clear diﬀ erences 
between the groups in length of stay in intensive-care 
units and hospitals (table 2). Surviving patients with ARDS 
in the salbutamol group needed a mean of 3∙4 more days 
(95% CI –0·3 to 7·1) in intensive-care units than did those 
in the placebo group (table 2). Serious adverse events 
(other than those recorded as trial outcomes, eg, death) 
were reported for 13 participants (nine in salbutamol 
group, four in placebo group). Four of these events were 
Salbutamol (n=161) Placebo (n=163) RR* or diﬀ erence† (95% CI)
Mortality 28 days after 
randomisation
55 (34%) 38 (23%) 1·47* (1·03 to 2·08)
Death before discharge 
from ICU
58 (36%) 45 (28%) 1·31* (0·95 to 1·80)
Death before discharge 
from hospital
62 (39%) 53 (33%) 1·18* (0·88 to 1·59)
Ventilator-free days 8·5 (8·8, 0-26) 11·1 (9·3, 0–27) –2·7† (–4·7 to –0·7)
Organ failure-free days 16·2 (10·7, 0–28) 18·5 (9·8, 0–28) –2·3† (–4·5 to –0·1)
Tachycardia suﬃ  cient to stop 
treatment with study drug
23 (14%) 2 (1%) 11·71* (2·81 to 48·88)
New arrhythmia suﬃ  cient to 
stop treatment with study drug
14 (9%) 3 (2%) 4·75* (1·39 to 16·23)
New lactic acidosis suﬃ  cient to 
stop treatment with study drug
10 (6%) 1 (<1%) 10·73* (1·36 to 84·82)
Duration of ICU stay (days) 17·6 (14·3, 0–85) 17·1 (14·0, 0–91) 0·5† (–2·6 to 3·6)
Duration of hospital stay (days) 32·5 (35·9, 0–191) 34·9 (36·3, 0–243) –2·4† (–10·3 to 5·5)
Duration of ICU stay with 
exclusion of deaths‡
20·5 (15·3, 3–85) 17·1 (12·6, 1–82) 3·4† (–0·3 to 7·1)
Serious adverse events recorded 9 (6%) 4 (2%) ··
Related to study drug 4 (3%) 0 ··
Related to study drug 
and unexpected
1 (<1%) 0 ··
Data are number (%) or mean (SD, range). RR=risk ratio. ICU=intensive-care unit. *Data are risk ratio. †Data show the 
diﬀ erence. ‡Salbutamol group, n=103; placebo group, n=118.
Table 2: Primary and secondary outcomes
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Figure 3: Kaplan-Meier curves for mortality
Rate of death in the two study groups up to 28 days after randomisation.
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thought to be related to the study drug infusion, and only 
one was an unexpected eﬀ ect. Subgroup analyses did not 
suggest that the eﬀ ects of salbutamol were modiﬁ ed by 
any of the variables investigated. For cause (categorical 
subgroup ing variable), the ratio of RRs was 0∙96 (95% CI 
0∙46–2∙01). For continuous variables the ratios of odds 
ratios for each variable investigated were 0∙97, 0∙93–1∙00; 
p=0∙07 for age; 1∙02, 0∙92–1∙14; p=0∙66 for severity of 
hypoxemia; and 1∙29, 0∙08–22∙04; p=0∙86 for mortality 
risk. The analysis suggested weak evidence of a possible 
interaction eﬀ ect with age. However, the eﬀ ect was small 
and strongly aﬀ ected by the oldest age stratum (>85 years), 
in which there were only four patients; therefore, this 
ﬁ nding is likely to be due to chance.
Adjustment for baseline variables (age, sex, PaO2/FIO2 
ratio, and cause) alone or in combination made no 
substantial diﬀ erence to the estimate of the treatment 
eﬀ ect of salbutamol or its statistical signiﬁ cance (data not 
shown). We obtained data for cause of death for 91 of 
93 patients who died by day 28 (55/55 in the salbutamol 
group, 36/38 in the placebo group). Because of the diversity 
of individual diagnoses, we grouped results for cause of 
death according to organ system. Diagnoses for the 
respiratory system were the most common primary cause 
of death in both groups (28 [51%] patients given salbutamol 
vs 20 [53%] given placebo), followed by multiorgan failure 
(12 [22%] vs 14 [37%]). ARDS was recorded on the death 
certiﬁ cate for 11 (21%) patients in the salbutamol group, 
and eight (21%) in the placebo group.
Discussion
Our ﬁ ndings show that intravenous salbutamol given to 
patients with early ARDS signiﬁ cantly increased 28-day 
mortality, and reduced ventilator-free days and organ 
failure-free days compared with those given placebo. 
Treatment was poorly tolerated because of tachycardia, 
arrhythmias, and lactic acidosis. These ﬁ ndings were 
unexpected; however, they have clariﬁ ed whether 
intravenous infusion of β-2 agonists should be used in 
patients with ARDS (panel). The ALTA trial23 of aerolised 
salbutamol for treatment of acute lung injury in 
282 patients
 
was stopped because the primary endpoint, 
ventilator-free days, had crossed predeﬁ ned futility 
boundaries, making the probability of a positive trial very 
low. Nevertheless, in that trial, clinical outcomes were 
worse in the salbutamol group than in the placebo group, 
particularly in the most severely ill patients. Because we 
recruited a large number of ARDS patients, with 
characteristics similar to other multicentre trials,2,23 from 
46 multidisciplinary intensive-care units in the UK, our 
data could be generalised to other intensive-care units.
Our trial has some limitations. First, mortality in the 
placebo group was much lower than anticipated. This 
outcome could have been caused by changes in the 
mortality of ARDS because of improvements in 
treatments.24 Second, because of the nature of pragmatic 
trials, we did not obtain prospective data for cardiovascular 
comorbidity and causes of deaths, including results of 
post-mortem. These data could provide useful infor mation 
about possible explanations of these unexpected trial 
results. Third, the trial was stopped at a smaller sample 
size than was planned; therefore, the precision of the 
treatment eﬀ ect estimates is lower than expected. A large 
sample size and narrow CIs might clarify salbutamol’s 
eﬀ ects on secondary outcomes, such as mortality rates in 
intensive-care units and hospitals. Fourth, although we 
recommended best practice for ARDS (protective 
ventilation, conservative ﬂ uid management), we did not 
measure details of clinical management. We selected the 
dose of salbutamol (15 μg/kg ideal bodyweight per
 
h) after 
an early dose-ranging study identiﬁ ed it to be the maximum 
dose that critically ill patients could receive without an 
increase in ventricular, atrial tachycardia, or ectopy. This 
dose was used in the BALTI study25 and resulted in steady-
state plasma concen trations of salbutamol (1×10-⁶ M), and 
is associated with a 100% increase in clearance of basal 
alveolar ﬂ uid in animal studies of ARDS. The dose is at the 
high end of the manufacturer’s recommended dosing 
regimen; as such, a beneﬁ cial eﬀ ect of salbutamol could 
have been outweighed by its adverse eﬀ ects at this dose. A 
lower dose of salbutamol might have produced a diﬀ erent 
outcome, so the conclusions from our study can relate only 
to the dose given.
Panel: Research in context
Systematic review
We searched PubMed and The Cochrane Library from Jan 1, 1960, to Aug 31, 2011, for 
randomised controlled trials or systematic reviews investigating the use of β agonists 
for the treatment of patients with established acute respiratory distress syndrome 
(ARDS). We used a combination of text (“salbutamol”, “beta agonist”, “ARDS”) and 
medical subject headings terms (“adrenergic beta-agonists”, “respiratory distress 
syndrome”, ”adult”). We identiﬁ ed two randomised controlled trials13,23 and no 
systematic reviews. Both trials were at low risk of bias, according to the criteria of the 
Cochrane risk of bias method.
The β-agonist lung injury trial (BALTI)13 recruited 40 patients and used an intravenous 
infusion of salbutamol. Findings from the trial showed reductions in extravascular lung 
water and plateau airway pressure in the group given salbutamol, but no diﬀ erence in 
28-day mortality (11 [58%] of 19 patients died in the salbutamol group vs 14 [67%] of 
21 in the placebo group).12 The aerosolised beta-2 agonist for treatment of acute lung 
injury (ALTA)23 trial randomly assigned 282 patients with acute lung injury to receive 
aerosolised salbutamol (5 mg) or placebo. The trial was stopped early on grounds of 
futility. The number of ventilator-free days (salbutamol 14·4 days vs placebo 16·6 days; 
95% CI for the diﬀ erence –4·7 to 0·3 days; p=0·087) or hospital mortality (35 [23%] of 
152 patients died in the salbutamol group vs 23 [17%] of 130 in the placebo group; 95% CI 
for the diﬀ erence –4·0 to 14·7; p=0·30) did not diﬀ er signiﬁ cantly.
Interpretation
The eﬀ ects on ventilator-free days and mortality in ALTA were consistent with those in 
BALTI-2, but our trial shows clearly that intravenous administration of salbutamol at 
15 μg/kg ideal bodyweight per
 
h to patients with early ARDS was poorly tolerated, is 
unlikely to be beneﬁ cial, and could worsen outcomes. Routine use of β-2 agonist therapy 
in mechanically ventilated patients with ARDS cannot be recommended.
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